Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;24(8):1053-1062.
doi: 10.1007/s11912-022-01270-8. Epub 2022 Apr 1.

Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies

Kristina Ihrmark Lundberg  1 , Diana Treis  1 , John Inge Johnsen  2
Affiliations
Review

Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies

Kristina Ihrmark Lundberg et al. Curr Oncol Rep. 2022 Aug.

Abstract

Purpose of review: The evolving information of the initiation, tumor cell heterogeneity, and plasticity of childhood neuroblastoma has opened up new perspectives for developing therapies based on detailed knowledge of the disease.

Recent findings: The cellular origin of neuroblastoma has begun to unravel and there have been several reports on tumor cell heterogeneity based on transcriptional core regulatory circuitries that have given us important information on the biology of neuroblastoma as a developmental disease. This together with new insight of the tumor microenvironment which acts as a support for neuroblastoma growth has given us the prospect for designing better treatment approaches for patients with high-risk neuroblastoma. Here, we discuss these new discoveries and highlight some emerging therapeutic options. Neuroblastoma is a disease with multiple facets. Detailed biological and molecular knowledge on neuroblastoma initiation, heterogeneity, and the communications between cells in the tumor microenvironment holds promise for better therapies.

Keywords: ALK inhibitors; Differentiation therapy; Tumor heterogeneity; Tumor microenvironment; Tumor plasticity.

PubMed Disclaimer

Conflict of interest statement

Kristina Ihrmark Lundberg, Diana Treis, and John Inge Johnsen declare they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Normal development of the sympathoadrenal lineage in humans. During neural crest development, Schwann cell precursor (SCPs) differentiate into both chromaffin cells and sympathoblasts [•, •]. The cell annotations in capital letters are genes that were expressed by the corresponding cells. SCPs, sympathoblasts, and chromaffin cells expressed these genes in both studies
See this image and copyright information in PMC

References

    1. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24(1):65–86. doi: 10.1016/j.hoc.2009.11.011. - DOI - PubMed
    1. Johnsen JI, Dyberg C, Fransson S, Wickström M. Molecular mechanisms and therapeutic targets in neuroblastoma. Pharmacol Res. 2018;1(131):164–176. doi: 10.1016/j.phrs.2018.02.023. - DOI - PubMed
    1. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;10:2. - PubMed
    1. PDQ Pediatric Treatment Editorial Board. Neuroblastoma Treatment (PDQ®): Health Professional Version. 2022 Feb 17. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK65747/
    1. Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A. 2010;107(9):4323–4328. doi: 10.1073/pnas.0910684107. - DOI - PMC - PubMed

Publication types